WXBMAIN WXB Futures(JAN5)
- 17.03
- +0.15+0.89%
WXB Futures(JAN5) News
WUXI BIO has been selected for the Dow Jones Sustainability Index for two consecutive years, ranking among the top.
For the second consecutive year, recognized in the Dow Jones Sustainability Index, demonstrating leadership in sustainable development. Leading the development of green biopharmaceuticals, technological innovation empowers a healthy future. Shanghai, January 2, 2025 / PR Newswire / -- WUXI BIO, a global leading contract research, development, and manufacturing (CRDMO) service company, announced that due to its unwavering efforts and outstanding achievements in promoting sustainable development, the company has been included in the 2024 Dow Jones Sustainability Index (DJSI) and ranks among the top in the Industry. DJSI provides investors with.
WuXi Biologics Ranks Top in 2024 Dow Jones Sustainability Indices for Second Consecutive Year
Minsheng Securities: Triple resonance moving upwards, focusing on pharmaceutical innovation and Consumer in 2025.
Looking ahead to 2025, there is a bullish outlook on the upward resonance of policy, fundamentals, and market sentiment, comprehensively optimistic about the pharmaceutical sector, with a focus on high-quality assets in pharmaceutical innovation and consumer sectors.
Hong Kong stocks are moving | CRO Concept stocks rose broadly in the morning, with most companies' overseas Business improving on a quarter-on-quarter basis. Institutions are Bullish on the Industry entering a stable growth phase.
CRO Concept stocks generally rose in the morning. As of the time of writing, Asymchem Laboratories (06821) rose by 4.16%, trading at 52.6 Hong Kong dollars; WUXI APPTEC (02359) rose by 3.53%, trading at 55.8 Hong Kong dollars; PHARMARON (03759) rose by 3.06%, trading at 14.14 Hong Kong dollars.
Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.
① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.
WuXi Biologics Included in UNGC 20 Case Examples of Sustainable Development for 20 Years Collection
Leading Green CRDMO Driven by Innovation for a Healthier Future Offering End-to-end Green Biologics Solutions for the Entire Industry SHANGHAI, Dec. 12, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio"
[Brokerage Focus] CEB International raises WUXI BIO (02269) Target Price by 68.5%. Global Biomedical financing recovery is Bullish on its valuation and performance recovery.
Jingwu Financial News | According to the Research Reports from CCB International, it is expected that the biosafety bill will most likely fail in legislation, which is Bullish for WUXI BIO (02269) to continue achieving performance growth in a relatively stable Operation environment. With the recovery of Global Biomedical financing, the bank is Bullish on the Company Valuation and performance recovery. The bank maintains a Buy rating for WUXI BIO and raises the Target Price based on DCF valuation to HKD 22.88 (previous value: HKD 13.58). The bank expects WUXI BIO's 2024E/25E/26E revenue to grow year-on-year by 7.1%/12.4%/13.9%, with adjusted Net income growing year-on-year by 0.8%/1.
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
The concept of contract research organizations started positively, wuxi bio (02269) rose by 13.03%, and the U.S. Biosafety Act was not included in the 2025 Fiscal Year Defense Authorization Act.
Jinwu Financial News | The contract research organizations concept started off positively, as of the time of publication, Wuxi Bio (02269) is up 13.03%, Wuxi AppTec (02359) is up 11.72%, Pharmaron (03759) is up 9.14%, Genscript Bio (01548) is up 4.98%, and Tigermed (03347) is up 4.87%. In terms of news, on December 7 local time in the USA, the final agreement text of the 2025 fiscal year National Defense Authorization Act (NDAA) released by the military committees of both the House and Senate did not include the biosafety act. Morgan Stanley stated, USA
Honkong stock market movement | CRO concept stocks collectively opened higher as the bioprotective legislation was not included in the final version of the NDAA by the U.S. Senate and House of Representatives.
CRO concept stocks opened higher collectively. As of the time of writing, wuxi bio (02269) increased by 13.03%, trading at 19.6 Hong Kong dollars; wuxi apptec (02359) rose by 11.72%, trading at 61 Hong Kong dollars; pharmaron (03759) climbed by 9.14%, trading at 16 Hong Kong dollars.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
Trending Industry Today: WUXI APPTEC Leads Gains In CRO Stocks
Hong Kong stocks unusual movement | CRO concept stocks expanded their gains, wuxi apptec (02359) surged 12% at one point. It is rumored that US legislators are considering making changes to the bioterrorism law.
CRO concept stocks further expanded their gains. As of the time of publication, wuxi apptec (02359) rose by 10%, trading at 55 Hong Kong dollars; pharmaron (03759) increased by 8.12%, trading at 14.64 Hong Kong dollars; wuxi bio (02269) went up by 7.02%, trading at 17.6 Hong Kong dollars.
Hong Kong stock movement | wuxi bio (02269) up over 3%. The company's advanced green manufacturing base in Ireland has achieved several important business progress.
Wuxi Bio (02269) rose more than 3%, as of the deadline for submission, it rose by 3.53%, closing at 17.02 Hong Kong dollars, with a trading volume of 0.238 billion Hong Kong dollars.
Wuxi Bio's Ireland facility has welcomed several milestones: multiple 16,000L scale PPQ production batches have been successfully completed and received HPRA GMP certification.
Successfully completed multiple 16,000-liter scale PPQ production, once again proving that disposable bioreactors are comparable to traditional stainless steel bioreactors in production efficiency. Obtained HPRA GMP certification, demonstrating that the company's new global operation has established a world-class quality system. Dundalk, Ireland, December 6, 2024 / PRNewswire / -- WuXi Biologics (2269.HK), a leading global contract research, development, and manufacturing organization (CRDMO), today announced significant business developments at its advanced green production base in Ireland.
[Brokerage Focus] Morgan Stanley slightly lowered the target price for wuxi bio (02269) by 1.25% and indicated that it will continue to maintain a leading position in the china market.
Jingu Wealth News | Morgan Stanley's report pointed out that Wuxi Bio (02269) occupies a leading position in the global biologics outsourcing service field, Its business model can not only obtain patent royalties from successfully listed drugs, but also its layout in late-stage projects provides strong momentum for the company's long-term growth. The bank believes that with its excellent technical strength and cost efficiency, Wuxi Bio will continue to maintain its leading position in the China market. The report mentioned that Morgan Stanley has raised its revenue forecast for Wuxi Bio for 2024 to 2026, expected to be 1.83 billion RMB and 2.03 billion RMB respectively.
Hong Kong stock abnormal | CRO concept stocks rebounded in the morning, overseas investment and financing gradually recovered. The pharmaceutical subdivision field and emerging businesses are expected to develop rapidly.
Concept stocks of CRO rebounded in early trading. As of the time of writing, Genscript Bio (01548) rose by 4.39% to HK$10.94; Tigermed (03347) rose by 4.47% to HK$33.85; Frontage (01521) rose by 2.75% to HK$1.12; Joinn Laboratories (06127) rose by 2.49% to HK$9.47; Wuxi Bio (02269) rose by 1.68% to HK$14.54.
Southwest Securities: CXO industry revenues are recovering season by season, but the demand for preclinical services still needs to be restored.
From a short-term perspective, commercial orders continue to be digested, putting pressure on the apparent performance of CDMO; overseas mature CXO clinical pipelines are steadily advancing, and the preclinical demand still needs to be restored.
Trending Industry Today: WUXI APPTEC Leads Losses In Biotechnology Stocks
Trending Industry Today: PHARMARON Leads Losses In CRO Stocks